References
Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest 39:1105–1114
Sedel F, Papeix C, Bellanger A et al (2015) High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 4(2):159–169
Barbesino G (2016) Misdiagnosis of Graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 26(6):860–863
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest or founding.
Ethical approval
All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.
Informed consent
Patient gave her informed consent for publication.
Rights and permissions
About this article
Cite this article
Cusini, C., Sassi, L., De Paola, G. et al. Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis. J Endocrinol Invest 40, 889–890 (2017). https://doi.org/10.1007/s40618-017-0678-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-017-0678-y